

**Thyroid Disease Committee meeting 9**

**Date:** 30 October 2018

**Location:** NGC Boardroom, Royal College of Physicians

**Minutes:** Final

<b>Committee members present:</b>		
Sarah Fishburn (SF) (Chair)		(Present for notes 1 – 7)
Anh Tran (AT)		(Present for notes 1 – 7)
Bijay Vaidya (BV)		(Present for notes 1 – 7)
Jean Munday (JM)		(Present for notes 1 – 7)
Karina Russell		(Present for notes 1 – 7)
Kristien Boelaert (KrB)		(Present for notes 1 – 7)
Mary Newton (MN)		(Present for notes 1 – 7)
Renee Hoenderkamp (RH)		(Present for notes 1 – 7)
Renuka Dias (RD)		(Present for notes 1 – 7)
Simon Pearce (SP)		(Present for notes 1 – 7)
		(Present for notes 1 – 7)
<b>Cooptees present:</b>		
Glenn Flux (GF)		(Present for notes 1 – 7)
Huw Griffiths (HG)		(Present for notes 1 – 7)
<b>In attendance:</b>		
Catherine McEvoy (CM)	Guideline Commissioning Manager	(Present for notes 1 – 7)
Carlos Sharpin (CS)	Associate Director/Guideline Lead	(Present for notes 1 – 7)
James Gilbert (JG)	Senior Research Fellow	(Present for notes 1 – 7)
Melina Vasileiou (MV)	Research Fellow	(Present for notes 1 – 7)
Shama Mahammed (SM)	Health Economist	(Present for notes 1 – 7)
Tamara Diaz (TD)	Project Manager	(Present for notes 1 – 7)
<b>Apologies:</b>		
Philip Newland Jones		
Mark Ballard		
Tim Cheetham		
David Haslall		
Judith McBride		

**1. Welcome, apologies and objectives of the meeting**

The Chair welcomed the Committee members and attendees to the ninth meeting of the Thyroid Disease Guideline Committee.

The Chair informed the Committee the apologies received. These are listed above.

The Chair outlined the objectives of the meeting.

## 2. Declarations of interest

Committee Declarations of Interest			
Insert initials	Declaration	Classification (as per the NICE DOI policy wording*)	Chair's action
KB	Comment submitted to Lancet Diabetes Endocrinology: "Liothyronine prescribing in the UK has changed dramatically with widespread variation by clinical commissioning group and is strongly influenced by economic deprivation."	Direct Non-financial	Non-Specific. Declare and participate.
	Research paper submitted to Thyroid: "Patients treated for hyperthyroidism are at increased risk of becoming obese: findings from a large prospective secondary care cohort."	Direct Non-financial	Non-Specific. Declare and participate.
	Research paper submitted to Thyroid: "Knowledge of Thyroid Eye Disease in Graves' Disease Patients With and Without Orbitopathy"	Direct Non-financial	Non-Specific. Declare and participate.
	Research paper submitted to Thyroid: "Risk of incident circulatory disease in patients treated for differentiated thyroid carcinoma with no history of cardiovascular disease."	Direct Non-financial	Non-Specific. Declare and participate.
	Wellcome Trust Collaborative Grant Submission: " <b>MIRACLE: Multicentre study of Iodine supplementation intRduced After Conception: Long-term Effects on child development</b> "	Direct Non-financial	Non-Specific. Declare and participate.
JM	Asked to join draft working party to amend low risk thyroid cancer guidelines.	Direct Non-financial	Non-Specific. Declare and participate.
BV	Co-authoring of a research paper published in Clinical Endocrinology: Patel KA, Knight B, Aziz A, Babiker T, Avades T, Findlay J, Cox S, Dimitropoulos I, Tysoe C, Panicker V, Vaidya B. Utility of systematic TSHR gene testing in adults with hyperthyroidism lacking overt autoimmunity and diffuse uptake on thyroid scintigraphy. Clin Endocrinol (Oxf). 2018 Oct 29. doi: 10.1111/cen.13892.	Direct Non-financial	Non-specific. Declare and participate.

MN	Member of the Working party of the Granta Practices Patient Participation Group (group of GP practices).	Direct Non-financial	Non-Specific. Declare
SP	Received speaker fee from Sanofi for educational talk on thyroid function and Graves' disease for neurology HCPs working with multiple sclerosis patients.	Direct Financial	Non-specific. Declare and participate.
	Letter submitted to JAMA on patient meta analysis.	Direct Non-financial	Non-Specific. Declare and participate.
GF	Membership of ICRP working party on the use of radiotherapeutics. Report concerns radiation safety aspects of the use of radiotherapeutics and states that patients administered fixed activities may be over treated.	Direct Non -financial	Specific. Declare and participate, to provide expert opinion on technical accuracy of the draft recommendation. To step out of the room during future meetings when the recommendation is finalized by the group.

The DOI register was made available to the Committee. The chair reviewed the DOI register and deemed that none of the original DOIs was in conflict with the agenda topics and clinical questions under discussion at the meeting. NICE DOI policy classifications are:

- Direct financial specific
- Direct financial non-specific
- Direct non-financial specific
- Direct non-financial non-specific
- Non-direct financial specific
- Non-direct financial non-specific

### 3. Update on Lay member participation:

3.1 The committee was updated on arrangements for lay member participation on the committee. The group heard that Annette Furley would continue to participate electronically but no longer attend meetings in person. The group was introduced to Karina Russell, who will attend all remaining meetings.

### 4. Minutes of GC 7&8:

4.1 The minutes of Committee Meetings 7&8 were agreed by the committee.

**5. Presentations and discussion:**

5.1 The evidence review on 'The safety of radioactive iodine' evidence review was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.

5.2 KB delivered an introductory presentation on Radioactive iodine side effects.

5.3 The evidence review on 'Antibodies' was presented to the committee by JG and SM. The group discussed the clinical and economic evidence and drafted recommendations for this area.

5.4 KB delivered an introductory presentation on Antibodies.

**6. Health Economics**

6.1 SM updated the committee on the health economic plan for the guideline.

**7. Any other business**

7.1 There being no further business the meeting ended at 1600.

**Date of next meeting:** 13 December 2018

**Location of next meeting:** Boardroom, Royal College of Physicians